Hornychova Helena, Melichar Bohuslav, Tomsova Marketa, Mergancova Jindøiska, Urminska Hana, Ryska Ales
Department of Pathology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic, EU.
Cancer Invest. 2008 Dec;26(10):1024-31. doi: 10.1080/07357900802098165.
Tumor-infiltrating leukocytes and other immunohistochemical parameters were evaluated in pretherapeutic biopsies and resection specimens in 73 patients undergoing neoadjuvant chemotherapy with doxorubicin and paclitaxel. Ten patients with pathological complete response had significantly higher p53 expression, CD3(+) lymphocyte and CD83(+) cell counts, and lower progesterone receptor expression. In the remaining 63 patients, a significant decrease in the percentage of Ki-67, vascular endothelial growth factor expression, CD68(+) monocytes, and increased CD31(+), CD34(+), and SMA(+) stromal vessels, maximal CD3(+) and CD56(+) lymphocyte, maximal and mean CD83(+) cell, maximal CD1a(+), and maximal and mean S100(+) cell counts were observed after neoadjuvant chemotherapy.
在73例接受阿霉素和紫杉醇新辅助化疗的患者的治疗前活检和切除标本中，评估肿瘤浸润白细胞和其他免疫组化参数。10例病理完全缓解的患者p53表达、CD3(+)淋巴细胞和CD83(+)细胞计数显著更高，而孕激素受体表达更低。在其余63例患者中，新辅助化疗后观察到Ki-67百分比、血管内皮生长因子表达、CD68(+)单核细胞显著降低，而CD31(+)、CD34(+)和SMA(+)基质血管、最大CD3(+)和CD56(+)淋巴细胞、最大和平均CD83(+)细胞、最大CD1a(+)以及最大和平均S100(+)细胞计数增加。
